Thymopentin

Thymopentin
Clinical data
Other names	(3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
ATC code	L03AX09 (WHO) ;
Identifiers
	IUPAC name L-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine;
PubChem CID	451417;
ChemSpider	397640 ;
UNII	O3Y80ZF13F;
KEGG	D06117 ;
ChEMBL	ChEMBL156025 ;
NIAID ChemDB	000127;
CompTox Dashboard (EPA)	DTXSID9046609 ;
ECHA InfoCard	100.242.320
Chemical and physical data
Formula	C30H49N9O9
Molar mass	679.76496 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1)C(C)C)CC(=O)O)CCCCN)[C@@H](N)CCC/N=C(\N)N;
	InChI InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 ; Key:PSWFFKRAVBDQEG-YGQNSOCVSA-N ;
(verify)

Thymopentin is an immunostimulant. As such, it has been used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in several patients for a brief time under specific treatments.[1][2][3]

It interacts with T cells.[4]

It is a thymic polypeptide.[5]

References

Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 322 (8352): 735–736. doi:10.1016/S0140-6736(83)92271-7. PMID 6193382.
Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". Int J Clin Pharmacol Res. 4 (6): 459–463. PMID 6398315.
Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Surv Immunol Res. 4 (1): supp1 58–62. doi:10.1007/BF02919057 (inactive 2019-12-03). PMID 3898293.
Liu Z, Zheng X, Wang J, Wang E (2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLoS ONE. 2 (12): e1348. doi:10.1371/journal.pone.0001348. PMC 2137936. PMID 18159232.
Peng Y, Chen Z, Yu W, et al. (July 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–71. doi:10.1016/j.cellbi.2008.07.011. PMID 18692582.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid6193382-1] Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 322 (8352): 735–736. doi:10.1016/S0140-6736(83)92271-7. PMID 6193382.

[pmid6398315-2] Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". Int J Clin Pharmacol Res. 4 (6): 459–463. PMID 6398315.

[pmid3898293-3] Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Surv Immunol Res. 4 (1): supp1 58–62. doi:10.1007/BF02919057 (inactive 2019-12-03). PMID 3898293.

[pmid18159232-4] Liu Z, Zheng X, Wang J, Wang E (2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLoS ONE. 2 (12): e1348. doi:10.1371/journal.pone.0001348. PMC 2137936. PMID 18159232.

[pmid18692582-5] Peng Y, Chen Z, Yu W, et al. (July 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–71. doi:10.1016/j.cellbi.2008.07.011. PMID 18692582.